Clinical trials: Intracutaneous Drug Delivery
- Condition Intracutaneous Drug Delivery
- Funder type Industry (pharma, biotech, devices)
- Has posted results yes
Dermatitis, Allergic Contact
Study of the Intradermal Injection of rHuPH20 or Placebo in Participants With Nickel Allergic Contact Dermatitis
The purpose of this study is to compare the effect and safety of rHuPH20 or placebo for the prevention and treatment of skin allergic reaction to nickel. The study drug and placebo will be administered by intradermal injection.
- Trial name
- NCT00928447
- Testing
- rHuPH20
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- Halozyme Therapeutics
Relapsing Remitting Multiple Sclerosis
ATX-MS-1467 in Patients With Relapsing Forms of Multiple Sclerosis
Phase 1 study to assess the safety and biological activity of ATX-MS-1467 in patients with relapsing forms of multiple sclerosis.
- Trial name
- NCT01097668
- Testing
- ATX-MS-1467
- Where
- 16 sites in Russia, United Kingdom
- Volunteers
- 43 people
- Sponsor
- Apitope Technology (Bristol) Ltd.
Meningococcal Infections, Meningitis
Safety and Immunogenicity of Intradermal Versus Subcutaneous Doses of Menomune®
The objective of this trial is to study the administration of the Menomune vaccine given intradermally and low-dose subcutaneously versus standard subcutaneously.
- Trial name
- NCT00850603
- Testing
- Meningococcal Polysaccharide Groups A\C\Y\W-135 Combined
- Where
- United States
- Volunteers
- 170 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Acute Migraine
Safety and Efficacy of ZP-Zolmitriptan Intracutaneous Microneedle Systems for the Acute Treatment of Migraine
This is a randomized, double-blind, multi-center, parallel-group study designed to compare the safety and efficacy of a range of doses of ZP-Zolmitriptan intracutaneous microneedle systems to placebo.
- Trial name
- Zotrip (NCT02745392)
- Testing
- ZP-Zolmitriptan
- Where
- 36 sites in United States
- Volunteers
- 365 people
- Sponsor
- Zosano Pharma Corporation
Graves Disease
ATX-GD-59 in Patients With Graves Disease Not Treated With Anti-thyroid Therapy
Phase 1 study to assess the safety and biological activity of ATX-GD-59 in patients with Graves Disease not currently treated with anti-thyroid therapy.
- Trial name
- NCT02973802
- Testing
- ATX-GD-59
- Where
- 8 sites in United Kingdom
- Volunteers
- 12 people
- Sponsor
- Apitope International NV
Diabetes, Diabetes Mellitus
Biolinq External Interferent Protocol
The primary objective of the study is to evaluate the interference effect of acetaminophen (APAP) on the Biolinq MicroArray Intradermal Continuous Glucose Biowearable System during a single in-clinic day on Day 3 of the sensor…
- Trial name
- NCT06560177
- Testing
- The Biolinq MicroArray Intradermal Continuous Glucose Biowearable System
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- Biolinq Inc.
Migraine
A Study to Evaluate the Long-Term Safety of M207 in the Acute Treatment of Migraine
This is an open-label, twelve-month safety study. There is a screening period followed by a run-in period to record migraine activity.
- Trial name
- ADAM (NCT03282227)
- Testing
- M207 Microneedle System
- Where
- 31 sites in United States
- Volunteers
- 342 people
- Sponsor
- Zosano Pharma Corporation
Allergic Skin Reaction
Evaluation of the Allergenicity of AMPHADASE INJECTION (Hyaluronidase Injection USP)
This study is designed to evaluate the allergenicity of Amphadase® in healthy volunteers using an intradermal skin test.
- Trial name
- H001-A2 (NCT01689363)
- Testing
- Hyaluronidase, Histamine, Saline
- Where
- 5 sites in United States
- Volunteers
- 253 people, healthy volunteers welcome
- Sponsor
- Amphastar Pharmaceuticals, Inc.
Diabetes, Diabetes Mellitus
Biolinq Safety and Effectiveness Trial
The primary objective of the study is to evaluate the safety and effectiveness of the Biolinq MicroArray Intradermal Continuous Glucose Biowearable System, which is intended to be worn for up to five (5) days (up to 120 hours) in…
- Trial name
- NCT06229743
- Testing
- Biolinq System
- Where
- 6 sites in United States
- Volunteers
- 247 people
- Sponsor
- Biolinq Inc.